Skip to main content
Clinical Trials/NCT04870073
NCT04870073
Withdrawn
Phase 3

Retrograde Autologous Priming for Preserving Hemoglobin Peri-operatively With or Without Mannitol: A Pilot Study

Hamilton Health Sciences Corporation1 site in 1 countrySeptember 21, 2022

Overview

Phase
Phase 3
Intervention
Conventional Priming
Conditions
Fluid Overload
Sponsor
Hamilton Health Sciences Corporation
Locations
1
Primary Endpoint
Feasibility Outcomes
Status
Withdrawn
Last Updated
3 years ago

Overview

Brief Summary

Hemodilution reduces concentrations of blood constituents: concentration of hemoglobin, red blood cells (hematocrit), physiological ions and coagulation factors that can contribute to impaired hemostasis and increasing the risk of perioperative blood transfusions. This pilot study will assess the feasibility of a large RCT to evaluate 2 techniques for reducing hemodilution during cardiac surgery: 1) retrograde autologous priming and 2) intraoperative mannitol. The aim of this pilot trial is to demonstrate feasibility of a larger trial to evaluate whether retrograde autologous priming and/or mannitol are superior to conventional priming alone.

Detailed Description

The use of large volumes of artificial priming fluids is still very high in cardiac surgery for routine CABG surgery with cardiopulmonary bypass. The resulting hemodilution is deleterious for patients and often requires counter measures to maintain fluid balance during and after surgery. Retrograde autologous priming and mannitol are simple low-cost solutions to the problem of hemodilution but their effectiveness, either alone or in combination, is unclear due to a lack of high-quality evidence. RAPPER-MAN is a single-centre 2x2 factorial cluster randomized trial. Participants will be randomly assigned (1:1:1:1 ratio) to the intervention groups: 1) Retrograde autologous priming (≥600 mL) + mannitol (0.3 g/kg bolus), 2) Retrograde autologous priming (≥600 mL) alone, 3) Conventional priming + mannitol (0.3 g/kg bolus), and 4) Conventional priming alone. The primary outcome is the change in hemoglobin concentration during cardiopulmonary bypass. Retrograde autologous priming will be performed within 10 minutes before, and mannitol will be added to the venous reservoir of the CPB machine within 5 minutes before, the start of cardiopulmonary bypass. The results of the larger trial are expected to have broad implications for fluid management in cardiac surgery in Canada.

Registry
clinicaltrials.gov
Start Date
September 21, 2022
End Date
September 21, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Andre Lamy

Cardiac Surgeon

Hamilton Health Sciences Corporation

Eligibility Criteria

Inclusion Criteria

  • ≥18 years of age.
  • Undergoing a first-time cardiac surgical procedure (i.e. isolated CABG, isolated single cardiac valve surgery or a combination of both or isolated ascending aorta replacement) with the use of cardiopulmonary bypass (CPB) and median sternotomy.

Exclusion Criteria

  • Left ventricle ejection fraction \<25%
  • Emergency surgery
  • History of bleeding disorder
  • Inherited thromboembolic or infective endocarditis (active)
  • Previous cardiac surgery
  • Severe renal impairment (serum creatinine \>250 μmol/L)
  • Hemoglobin \<80 g/L
  • Thrombocytopenia (\<50,000 platelets per μL)
  • Expected circulatory arrest
  • Body weight ≤50 kg

Arms & Interventions

Conventional priming alone

Participants will receive conventional priming alone.

Intervention: Conventional Priming

Retrograde autologous priming alone

Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.

Intervention: Retrograde autologous priming

Retrograde autologous priming + mannitol

Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.

Intervention: Retrograde autologous priming

Retrograde autologous priming + mannitol

Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.

Intervention: Mannitol

Conventional priming + mannitol

Participants will receive conventional priming. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.

Intervention: Mannitol

Conventional priming + mannitol

Participants will receive conventional priming. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.

Intervention: Conventional Priming

Outcomes

Primary Outcomes

Feasibility Outcomes

Time Frame: Start to end of study recruitment, which is anticipated to take 20 weeks

Feasibility will be established in the pilot phase if all the following criteria are met: 1. Average recruitment rate of 7 patients per week. 2. Complete Hb data before and after cardiopulmonary bypass in 90% of patients. 3. Compliance of the research team members, OR staff and ward medical staff with the protocol of 90%.

Change in hemoglobin concentration during cardiopulmonary bypass

Time Frame: Start to end of cardiopulmonary bypass

Change in arterial hemoglobin concentration during cardiopulmonary bypass

Secondary Outcomes

  • Change in hemoglobin concentration after cardiopulmonary bypass(Start of cardiopulmonary bypass to hospital discharge or 5 days maximum (whichever occurs first))

Study Sites (1)

Loading locations...

Similar Trials